Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers

Andrew J. Armstrong, Matthew S. Marengo, Sebastian Oltean, Gabor Kemeny, Rhonda L. Bitting, James D. Turnbull, Christina I. Herold, Paul K. Marcom, Daniel J. George, Mariano Garcia-Blanco

Research output: Contribution to journalArticle

384 Citations (Scopus)

Abstract

During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal- epithelial transitions (MET) as part of a broad invasion and metastasis program. We previously observed MET events among lung metastases in a preclinical model of prostate adenocarcinoma that suggested a relationship between epithelial plasticity and metastatic spread. We thus sought to translate these findings into clinical evidence by examining the existence ofEMTin circulating tumor cells (CTC) from patients with progressive metastatic solid tumors, with a focus on men with castration-resistant prostate cancer (CRPC) and women with metastatic breast cancer. We showed that the majority (>80%) of these CTCs in patients with metastatic CRPC coexpress epithelial proteins such as epithelial cell adhesion molecule (EpCAM), cytokeratins (CK), and E-cadherin, with mesenchymal proteins including vimentin, N-cadherin and O-cadherin, and the stem cell marker CD133. Equally, we found that more than 75% of CTCs from women with metastatic breast cancer coexpress CK, vimentin, and N-cadherin. The existence and high frequency of these CTCs coexpressing epithelial, mesenchymal, and stem cell markers in patients with progressive metastases has important implications for the application and interpretation of approved methods to detect CTCs.

Original languageEnglish (US)
Pages (from-to)997-1007
Number of pages11
JournalMolecular Cancer Research
Volume9
Issue number8
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Cadherins
Epithelial-Mesenchymal Transition
Prostatic Neoplasms
Breast Neoplasms
Castration
Vimentin
Neoplasm Metastasis
Keratins
Mesenchymal Stromal Cells
Prostate
Neoplasms
Proteins
Adenocarcinoma
Stem Cells
Epithelial Cells
Lung

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology

Cite this

Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. / Armstrong, Andrew J.; Marengo, Matthew S.; Oltean, Sebastian; Kemeny, Gabor; Bitting, Rhonda L.; Turnbull, James D.; Herold, Christina I.; Marcom, Paul K.; George, Daniel J.; Garcia-Blanco, Mariano.

In: Molecular Cancer Research, Vol. 9, No. 8, 08.2011, p. 997-1007.

Research output: Contribution to journalArticle

Armstrong, AJ, Marengo, MS, Oltean, S, Kemeny, G, Bitting, RL, Turnbull, JD, Herold, CI, Marcom, PK, George, DJ & Garcia-Blanco, M 2011, 'Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers', Molecular Cancer Research, vol. 9, no. 8, pp. 997-1007. https://doi.org/10.1158/1541-7786.MCR-10-0490
Armstrong, Andrew J. ; Marengo, Matthew S. ; Oltean, Sebastian ; Kemeny, Gabor ; Bitting, Rhonda L. ; Turnbull, James D. ; Herold, Christina I. ; Marcom, Paul K. ; George, Daniel J. ; Garcia-Blanco, Mariano. / Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. In: Molecular Cancer Research. 2011 ; Vol. 9, No. 8. pp. 997-1007.
@article{debfd075e7444e0091f35c30ba39b0fa,
title = "Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers",
abstract = "During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal- epithelial transitions (MET) as part of a broad invasion and metastasis program. We previously observed MET events among lung metastases in a preclinical model of prostate adenocarcinoma that suggested a relationship between epithelial plasticity and metastatic spread. We thus sought to translate these findings into clinical evidence by examining the existence ofEMTin circulating tumor cells (CTC) from patients with progressive metastatic solid tumors, with a focus on men with castration-resistant prostate cancer (CRPC) and women with metastatic breast cancer. We showed that the majority (>80{\%}) of these CTCs in patients with metastatic CRPC coexpress epithelial proteins such as epithelial cell adhesion molecule (EpCAM), cytokeratins (CK), and E-cadherin, with mesenchymal proteins including vimentin, N-cadherin and O-cadherin, and the stem cell marker CD133. Equally, we found that more than 75{\%} of CTCs from women with metastatic breast cancer coexpress CK, vimentin, and N-cadherin. The existence and high frequency of these CTCs coexpressing epithelial, mesenchymal, and stem cell markers in patients with progressive metastases has important implications for the application and interpretation of approved methods to detect CTCs.",
author = "Armstrong, {Andrew J.} and Marengo, {Matthew S.} and Sebastian Oltean and Gabor Kemeny and Bitting, {Rhonda L.} and Turnbull, {James D.} and Herold, {Christina I.} and Marcom, {Paul K.} and George, {Daniel J.} and Mariano Garcia-Blanco",
year = "2011",
month = "8",
doi = "10.1158/1541-7786.MCR-10-0490",
language = "English (US)",
volume = "9",
pages = "997--1007",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers

AU - Armstrong, Andrew J.

AU - Marengo, Matthew S.

AU - Oltean, Sebastian

AU - Kemeny, Gabor

AU - Bitting, Rhonda L.

AU - Turnbull, James D.

AU - Herold, Christina I.

AU - Marcom, Paul K.

AU - George, Daniel J.

AU - Garcia-Blanco, Mariano

PY - 2011/8

Y1 - 2011/8

N2 - During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal- epithelial transitions (MET) as part of a broad invasion and metastasis program. We previously observed MET events among lung metastases in a preclinical model of prostate adenocarcinoma that suggested a relationship between epithelial plasticity and metastatic spread. We thus sought to translate these findings into clinical evidence by examining the existence ofEMTin circulating tumor cells (CTC) from patients with progressive metastatic solid tumors, with a focus on men with castration-resistant prostate cancer (CRPC) and women with metastatic breast cancer. We showed that the majority (>80%) of these CTCs in patients with metastatic CRPC coexpress epithelial proteins such as epithelial cell adhesion molecule (EpCAM), cytokeratins (CK), and E-cadherin, with mesenchymal proteins including vimentin, N-cadherin and O-cadherin, and the stem cell marker CD133. Equally, we found that more than 75% of CTCs from women with metastatic breast cancer coexpress CK, vimentin, and N-cadherin. The existence and high frequency of these CTCs coexpressing epithelial, mesenchymal, and stem cell markers in patients with progressive metastases has important implications for the application and interpretation of approved methods to detect CTCs.

AB - During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal- epithelial transitions (MET) as part of a broad invasion and metastasis program. We previously observed MET events among lung metastases in a preclinical model of prostate adenocarcinoma that suggested a relationship between epithelial plasticity and metastatic spread. We thus sought to translate these findings into clinical evidence by examining the existence ofEMTin circulating tumor cells (CTC) from patients with progressive metastatic solid tumors, with a focus on men with castration-resistant prostate cancer (CRPC) and women with metastatic breast cancer. We showed that the majority (>80%) of these CTCs in patients with metastatic CRPC coexpress epithelial proteins such as epithelial cell adhesion molecule (EpCAM), cytokeratins (CK), and E-cadherin, with mesenchymal proteins including vimentin, N-cadherin and O-cadherin, and the stem cell marker CD133. Equally, we found that more than 75% of CTCs from women with metastatic breast cancer coexpress CK, vimentin, and N-cadherin. The existence and high frequency of these CTCs coexpressing epithelial, mesenchymal, and stem cell markers in patients with progressive metastases has important implications for the application and interpretation of approved methods to detect CTCs.

UR - http://www.scopus.com/inward/record.url?scp=80051988763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051988763&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-10-0490

DO - 10.1158/1541-7786.MCR-10-0490

M3 - Article

VL - 9

SP - 997

EP - 1007

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 8

ER -